WASHINGTON, May 30 (UPI) --The drug goserelin, sold by AstraZeneca under the brand name Zoladex, may help protect the ovaries of women with breast cancer. "It's not a panacea, but based on these data, ...

February 25, 2009 — In premenopausal women with early breast cancer, adjuvant therapy with the luteinizing hormone-releasing hormone agonist goserelin (Zoladex, AstraZeneca) decreases the long-term ...

Goserelin is a type of hormone therapy. It is also known as Zoladex. You pronounce goserelin as gos-er-e-lin. This page is about goserelin for breast cancer in women who haven’t gone through menopause ...

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. A drug that reduces the amount of estrogen in the body can help prevent ...

All premenopausal women who had been treated with goserelin and anastrozole for advanced breast cancer in the Nottingham Breast Unit were included in the study. A total of 16 such patients with a mean ...

AstraZeneca has sold the rights to its big-selling cancer drug Zoladex in Canada and the US to TerSera Therapeutics, as the UK firm moves to focus on its newer oncology products. The deal, which is ...

Medical oncologists want to know whether a new drug combination can slow the progression of male breast cancer, a rare disease that often goes undiagnosed until it's in an advanced stage. Zeina Nahleh ...

Goserelin, a lutenizing hormone-releasing hormone agonist, reduces the long-term risk of disease recurrence and deaths in premenopausal women with early breast cancer who did not take tamoxifen, ...

Goserelin, a lutenizing hormone-releasing hormone agonist, reduces the long-term risk of disease recurrence and deaths in premenopausal women with early breast cancer who did not take tamoxifen, ...